Compare PROP & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | BEAT |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6M | 82.7M |
| IPO Year | N/A | 2021 |
| Metric | PROP | BEAT |
|---|---|---|
| Price | $2.02 | $2.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.75 | $6.75 |
| AVG Volume (30 Days) | 1.5M | ★ 11.1M |
| Earning Date | 02-15-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,577,000.00 | N/A |
| Revenue This Year | $3,967.26 | N/A |
| Revenue Next Year | $71.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.54 |
| 52 Week High | $10.58 | $4.00 |
| Indicator | PROP | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 64.41 | 52.26 |
| Support Level | $1.71 | $2.23 |
| Resistance Level | $1.94 | $2.60 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 94.68 | 21.37 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.